Everyone is looking for the best way to play the massive wave of global supply-chain duplication and reshoring. This analysis examines why the market’s current favourite answer—buying the companies that supply physical equipment and consumables to these new factories—fundamentally misprices the real bottleneck of the late 2020s. The true scarcity is no longer the physical capacity to build; it is the legal right to operate.
9–15x Operating Earnings
The market currently misprices major testing and certification groups as cyclical industrial consultants. Historically, these businesses command multiples between 15x and 20x. The upside here is driven by a structural reclassification—the market recognizing them as highly resilient compliance annuities—rather than chasing unrealistic, software-like margins.
31 December 2030
The legally binding deadline for the European Train Control System (ERTMS) to be fully operational across core rail corridors. With only 10–15% of the network currently equipped, this represents the single hardest regulatory cliff—and the clearest investment catalyst for integrators—in this entire analysis.
29 September 2026
The critical enforcement deadline where certain pharmaceutical tariffs default to 100% for companies lacking pre-cleared onshoring agreements. Whether regulators strictly enforce this—or cave to mass exemptions—will prove whether the promised wave of duplicated factory builds is economically real or just political theater.
The following overview summarizes the strategic building blocks, position directions, and allocated companies for this research theme.
These are the companies that governments deputise to enforce their rules. They collect more mandates as regulatory requirements expand and gain delegated inspection work when the state must outsource its backlog.
These specialised engineers validate new facilities. The credential, rather than the wage, is the barrier to entry, but the businesses are currently priced as standard cyclical staffing consultancies.
EU rail signalling faces a legally binding core-network deadline of 31 December 2030, protected by a strict certification firewall. The underlying companies trade at modest valuations without a thematic premium.
This is an opportunistic position rather than a core holding. Buy only on price dips, preferring essential filtration and media over chromatography resins.
This is a source of funds for the rest of the portfolio. The 2027–29 capacity wave is real, but rising Asian competition may weaken cash quality before passive thematic ownership reacts.
Fragmentation is no longer just a temporary political phase; it is hardening into permanent administrative infrastructure. But the binding constraint has migrated. Duplicated plants, power grids and rail corridors are being built, but the governments that mandated them cannot inspect, certify or verify them fast enough.
Through the early 2030s, the global economy will run a queue. Inspection slots, validated engineering headcount and accredited laboratory capacity are strictly rationed. The political resolution to this backlog is to deputise.
An entire permanent industry is hardening around attesting to attributes rather than manufacturing physical goods: verifying carbon content through CBAM, material origin, recycled content, digital product passports through ESPR, and cybersecurity conformity. These services are priced per site, per tonne or per product line. They are indexed to regulatory ratchets, funded entirely outside government budgets, and are largely immune to broader economic cycles.
Critics argue that the core TIC trade is too slow. Policy sparks are priced in immediately on announcement; by the time the steady accumulation of mandates is obvious to everyone, the easy money has been made.
Response: We are intentionally swapping the hope of a speculative triple-digit return for a highly probable, steady compounder. That is investment discipline, not a flaw.
The same policy that gives these testing companies more volume also opens the door to cheaper, third-country certifiers being recognised by Western governments. If price competition arrives faster than the number of mandates grows, these companies could be trapped as low-margin volume businesses forever.
Regulatory compliance has no flashy sector tag, no clean stock screener and no dedicated ETF plumbing. You can be entirely right about the economics and still see the stock move slowly because passive money is not forced to buy it. Grid equipment, owned broadly as an “AI data-centre” proxy, can keep rising on blind thematic momentum.
Will the EU’s current push to cut red tape thin out upcoming regulations such as digital product passports and deforestation rules? If so, the core thesis loses some of its fuel.
Will the legally binding 2030 deadline for European rail signalling survive? If governments divert infrastructure funds to other pressing needs, this mandate could be delayed, converting a sharp, profitable regulatory cliff into a sluggish, ordinary industrial cycle.
| Rank | Layer | Rationale for margin capture |
|---|---|---|
| 1 | I. Adjudicators and Deputies (The Core) | Testing, Inspection and Certification groups, notified regulatory bodies and software registries that host digital product passports collect many small, mandatory payments. The revenue adjusts for inflation, does not depend heavily on economic booms, and is built on thousands of compliance checks. The market currently values these companies at roughly 9–15× operating earnings, often mistaking them for standard consulting firms. As regulations stack up, the valuation could climb toward 16–20× earnings. |
| 2 | II. Certified Human Capital and Validation Services | Specialised validation engineers, nuclear quality-assurance staff and certified high-voltage technicians hold the most mispriced layer. These businesses are valued at 8–12× earnings as if they were temporary staffing agencies, although their credentials and experience create a monopoly on bottleneck capacity. The strongest companies are private, so listed exposure must be bought selectively. |
| 3 | III. Holders of Live Certificates | Facilities that already hold the legal approvals to operate, such as sterile pharmaceutical plants, approved nuclear-component manufacturers and licensed aviation-maintenance hubs, enjoy a five-to-eight-year scarcity premium. New competitors remain in the regulatory waiting room, but this advantage will fade as regulators clear the backlog. |
| 4 | IV. Per-Batch Consumables | Bioprocessing media, filters and single-use manufacturing volumes are widely loved by the market but structurally challenged. Growth is capped by the speed at which regulators approve new factories, while process intensification can reduce the raw materials required for the same product output. |
The durable economics sit with accepted proof, certified capacity and dated technical obligations. Equipment manufacturers remain exposed to rising competition once the physical capacity wave catches up with demand.
The selection below is organised by economic role. Leeway ratings describe each company independently of this research topic; they are not a substitute for the arguments on this page.
The Business-Rating scores the quality of the business model, independent of the share price. The Market-Fit-Rating tests eighteen fundamental figures for how well the company currently fits the market; a negative reading implies expected negative performance. The Cycle-Rating places the valuation in the stock’s own history: a higher figure means the shares are historically cheaper. The Leeway-Score combines the three in equal parts. How the ratings are calculated
From 19 August 2026 to 4 September 2026: Portfolio-0.8%ACWI+0.7%
These are the companies that governments deputise to enforce their rules. They collect more mandates as regulatory requirements expand and gain delegated inspection work when the state must outsource its backlog.
Role in thesis: Provides the broadest exposure to the growing sum of compliance duties, including origin and content attestation, carbon verification, product conformity, and drug manufacturing audits.
Valuation context: Each individual duty is small, but the aggregate volume grows with every new regulation. Pricing is typically linked to inflation, offering a steady, compounding revenue base.
Invalidation risk: Operating margins are structurally capped near 20%. A Swiss franc cost base and a history of heavy acquisitions make organic growth difficult to parse. The market re-rating will likely be gradual rather than immediate.
Role in thesis: A testing group with the cleanest focus on infrastructure, marine classification, and building and energy certification.
Valuation context: A ship’s classification is a legal prerequisite for its operation. This exact logic is now being applied to carbon border levies, construction, and offshore assets, providing recurring, mandate-driven revenue without requiring software-like valuations.
Invalidation risk: Shipping and industrial capital spending are inherently cyclical. The company’s growth relies partly on acquisitions, and margins face the same structural ceiling as its peers. Any failed M&A activity would likely pressure the share price.
Role in thesis: A high-margin testing group heavily geared toward the conformity and certification of individual products.
Valuation context: Emerging eco-design regulations are shifting compliance from a one-off type approval into recurring, per-batch testing. This creates a new and durable stream of recurring income that aligns closely with Intertek’s core business.
Invalidation risk: A substantial portion of revenue is tied to consumer goods, making it vulnerable to consumer spending cycles. The valuation discount associated with its London listing may persist indefinitely, and product passport revenues will remain a small part of the total base for years.
Role in thesis: An extensive accredited laboratory network covering food, environment, drug testing, and clinical work.
Valuation context: Currently the most attractively priced large company in the testing and certification space. Testing for PFAS chemicals and food safety drives volume independently of the broader macroeconomic cycle.
Invalidation risk: The primary risks are governance-related rather than operational. Founder control, family-owned laboratory properties, complex reporting, and heavy acquisition accounting mean minority shareholders are not always the priority. Position sizing should reflect this risk.
Role in thesis: Safety-certification gatekeeper for electrical equipment, batteries, energy storage and renewable hardware.
Valuation context: The UL mark is effectively a prerequisite for market access in North America and increasingly elsewhere. UL Solutions therefore earns from the electrification build-out without carrying the manufacturers' capacity cycle or pricing risk. The value lies in the certification mandate, not in a technology premium.
Invalidation risk: The shares have already re-rated partly since the 2024 listing, so the entry-price argument is weaker here. A release of shares from the founding trust, US revenue concentration and competition between certification providers remain risks. The thesis is invalidated if the mark loses its practical market-access force or pricing no longer covers the credentialed cost base.
Role in thesis: Accredited laboratory exposure across life sciences, environmental, food and minerals testing, with an Australian listing outside the crowded European testing screen.
Valuation context: Environmental and PFAS testing are regulatory obligations with per-sample economics, while life-science testing adds a less cyclical source of demand. ALS captures the same adjudication and proof requirement through a different geography and investor base.
Invalidation risk: The minerals division links a meaningful share of earnings to exploration cycles and gold prices, while Australian-dollar exposure adds another variable. The commodity cycle has already helped the valuation. The thesis is invalidated if mandated testing growth fails to offset minerals cyclicality or if margins no longer compensate for the laboratory cost base.
Role in thesis: China’s largest independent provider of testing, inspection, and certification services.
Valuation context: Regulatory fragmentation is a global trend. China is building its own mandatory certification, carbon accounting, and food safety frameworks. As a domestic accredited laboratory, CTI captures this work without needing to compete for Western accreditations.
Invalidation risk: Domestic price competition in the Chinese testing market is severe and has compressed margins. Restricted access to A-shares, lower disclosure standards, and two-way geopolitical policy risks mean this should be sized as a small, diversifying position.
Role in thesis: Serialisation, track-and-trace and inspection infrastructure for proving what a medicine or food product is and where it came from.
Valuation context: This is a direct listed expression of per-product attestation. Pharmaceutical serialisation, food traceability and digital product passports turn regulatory proof into a recurring technology requirement, while the market has largely abandoned the company after its execution failures.
Invalidation risk: The company is small, thinly traded and carries a difficult margin, balance-sheet and governance history. Customers can defer capex, and the investment case is exposed to execution more than the larger testing groups. The thesis is invalidated if product-passport and serialisation mandates are delayed or if the evidence layer becomes a low-margin commodity.
Role in thesis: A provider of non-destructive testing for critical infrastructure, including pipelines, refineries, bridges, and aerospace structures.
Valuation context: These inspections are legally mandated on strict schedules, regardless of whether the customer is actively investing in new capital projects. The business is constrained by the availability of certified inspectors, not by end-market demand.
Invalidation risk: The company carries high leverage, thin margins, heavy dependence on oil and gas customers, and struggles with the imperfect pass-through of rising wages. The stock has been cheap for a decade and requires a clear operational catalyst to re-rate.
Role in thesis: A supplier of metrology equipment and assured positioning and timing systems.
Valuation context: Regulatory conformity must be precisely measured. Hexagon supplies the necessary measurement equipment across manufacturing and construction, while its navigation segment provides a resilient backup option in the event of satellite outages.
Invalidation risk: The company is a complex software and industrial hybrid with an acquisition-heavy history and opaque segment reporting. Automotive and construction end-markets are cyclical, and ongoing corporate separation plans carry execution risk.
These specialised engineers validate new facilities. The credential, rather than the wage, is the barrier to entry, but the businesses are currently priced as standard cyclical staffing consultancies.
Role in thesis: Provides certified engineering capacity for the process industry, pharmaceutical plants, rail, and energy systems.
Valuation context: It is currently valued like a standard Nordic staffing business, despite owning the actual scarce resource: credentialed engineers. Its order backlog provides early visibility into whether announced factory builds are actually moving forward.
Invalidation risk: Margins depend heavily on high utilisation rates and will fall if any single end-market softens. Nordic construction exposure and a persistent gap between the bottleneck narrative and actual delivered margins remain headwinds. The re-rating requires the market to stop valuing it as a generic consultancy.
Role in thesis: Certified engineering platform focused on water, environmental remediation, mobility and other regulated infrastructure programmes.
Valuation context: Remediation, PFAS liability assessment, water compliance and rail programmes are obligations rather than discretionary projects. Arcadis sells the credentialed engineering labour needed to discharge them and offers a broader geographic expression of the same bottleneck as AFRY.
Invalidation risk: Project execution, legacy claims, delayed margin targets and currency translation can overwhelm the regulatory-demand argument. The overlap with AFRY is substantial, so the two should not be treated as independent exposures. The thesis is invalidated if mandated project demand does not translate into backlog conversion and durable margins.
EU rail signalling faces a legally binding core-network deadline of 31 December 2030, protected by a strict certification firewall. The underlying companies trade at modest valuations without a thematic premium.
Role in thesis: The leading European supplier of the common train control system and its on-board technology.
Valuation context: The position is supported by a buyer compelled by law, a hard deadline, and a consolidated supplier list protected by official approvals. Signalling is the highest-margin part of the business mix and must be procured by 2030, offering upside for a stock punished by recent capital crises.
Invalidation risk: Governments facing tight budgets could formally delay the 2030 deadline. In the near term, lower-margin rolling-stock contracts and working-capital swings drive earnings, masking the strength of the signalling division. The balance sheet is repaired, but not robust.
Role in thesis: A secondary, more attractively priced route into train control, alongside Iberian and export rail capital spending.
Valuation context: CAF trades at a substantial valuation discount to the sector despite a record order backlog. Its signalling arm benefits from the same European retrofit wave without the index weight and crowding of its larger French rival.
Invalidation risk: The company is small and thinly traded. The bus segment dilutes the pure rail narrative, and it has a history of low-margin, fixed-price contracts. Signalling financials are not disclosed in a way that allows the market to value the division entirely separately.
Role in thesis: A provider of rail infrastructure, including fastenings, switches, and lifecycle maintenance.
Valuation context: Track components are approved at a national level, consumed during regular operation, and limited by available labour. The position is supported by Germany’s infrastructure fund and European corridor renewals, which are fully funded and dated.
Invalidation risk: The company is controlled by a majority shareholder. Its China business has been a persistent drag, and the pace of German government disbursements is a political variable. This is a hardware business, earning on the civil works of the deadline rather than on higher-margin digital intelligence.
Role in thesis: A supplier of rail systems, including braking and on-board control, supported by a large spare-parts business.
Valuation context: Brakes and control systems are safety-certified and approved country by country. The spare-parts business generates recurring revenue from these approvals in ongoing operations. The acquisition of Alstom’s North American signalling assets adds a second retrofit growth line.
Invalidation risk: In the near term, the weaker commercial-truck business drives earnings and sentiment. Family ownership and past governance turbulence remain concerns, and the margin-improvement programme is still unproven. Signalling remains a small part of a large, mixed group.
This is an opportunistic position rather than a core holding. Buy only on price dips, preferring essential filtration and media over chromatography resins.
Role in thesis: A manufacturer of elastomer closures, plungers, and seals that are hardwired into drug regulatory dossiers.
Valuation context: Switching suppliers requires a formal regulatory change, creating immense customer lock-in. Every new sterile line consumes these specified parts. The stock is currently overlooked after years of disappointing earnings.
Invalidation risk: A Swiss small-cap with thin liquidity and a controlling family. Execution and margin recovery have disappointed repeatedly, and the industrial divisions dilute the healthcare focus. The real consumption step-up occurs between 2028 and 2031, leaving a potential dead interval in the near term.
Role in thesis: A supplier of primary packaging, drug delivery systems, and validated filling equipment.
Valuation context: The company captures both the upfront equipment sales for new lines and the recurring consumable revenue written into approvals. The current valuation discount stems from recent guidance cuts, not a deterioration of its competitive position.
Invalidation risk: Italian family control with a US listing. Capacity expansions have been the source of recent disappointments, and equipment revenue is notoriously lumpy. Best accumulated after a disappointment rather than in anticipation of a strong earnings print.
Role in thesis: A best-in-class provider of consumables for biotechnology manufacturing.
Valuation context: Process efficiencies reduce the need for certain resins but increase demand for media and filters. Sartorius is well positioned to capture this shifting recurring revenue stream as new facilities come online.
Invalidation risk: This is a highly crowded trade. It commands a steep multiple on depressed earnings and is under active specialist surveillance, meaning good news is priced in instantly. Earnings can rise, but multiple expansion is highly unlikely. It is viable only on significant drawdowns.
This is a source of funds for the rest of the portfolio. The 2027–29 capacity wave is real, but rising Asian competition may weaken cash quality before passive thematic ownership reacts.
Role in thesis: A provider of certified offshore installation and subsea cable laying with its own repair capacity.
Valuation context: Installing interconnectors and subsea cables is constrained by specialised vessels and certified jointing crews, not by factory capacity. This is the one grid-adjacent business that the Asian equipment-capacity wave does not commoditise.
Invalidation risk: A Belgian mid-cap exposed to project execution and weather risks. US offshore wind policy heavily influences sentiment and earnings. The business is lumpy and will likely trade on offshore-wind macro factors regardless of the grid-resilience narrative.
Role in thesis: Fade exposure to grid and energy equipment, held as a funding source and benchmark against the certified-service and rail positions rather than as a conventional short.
Valuation context: The terminal scarcity narrative is already reflected in the multiple and record backlog. New transformer, electrical-steel and cable capacity from 2027 should make tendering more competitive, allowing unit volumes to rise while the price per unit of capacity falls. The trade is against peak economics, not against the reality of grid investment.
Invalidation risk: This is an underweight, not a short. The shares are widely held as an AI data-centre proxy, and thematic flows can ignore deteriorating cash quality for several quarters. The thesis is invalidated if capacity additions fail to arrive, competitive tender prices do not flatten or persistent HVDC and grid bottlenecks keep returns above the expected fade path.
Role in thesis: A hedge against the broader underweight stance on grid equipment, specifically through exposure to high-voltage direct current.
Valuation context: Converter halls, valve technology, and European interconnection remain genuine bottlenecks that new Asian transformer plants cannot resolve. Siemens Energy is included for symmetry if HVDC scarcity persists longer than anticipated.
Invalidation risk: The troubled wind division can overwhelm the grid narrative in either direction. The stock has already re-rated substantially and is widely discovered by the market.
| When | What happens | Why it matters |
|---|---|---|
| 29 September 2026 | 29 September 2026: Certain pharmaceutical tariffs default to 100% for companies outside pre-cleared agreements. | Whether governments enforce this tariff or grant mass exemptions is the ultimate test of whether the mandated factory duplication is real. |
| 1 January 2027 | TIC organic growth is split into price and volume. | This metric will show whether regulatory accreditation is a highly profitable moat or merely a commoditised service. |
| 1 January 2027 | CBAM and ESPR rollouts begin to create operational obligations, including digital battery passports from 2027. | Each specific legal act matters more than the headline political promise. |
| deputisedState.calendar.open | Grid equipment exit triggers: large-transformer lead times shorten towards 24 months, tender prices flatten, or customer advance payments roll over. | Two of these three signals are required before fully exiting grid equipment. |
| Path | Weight | What happens |
|---|---|---|
| Bull Case (22%) — The mandate stack gets a name | 22% | Digital passports, carbon tariffs and strict manufacturing obligations land exactly on schedule. Rail signalling contracts surge with fresh infrastructure funding. The broader market recognises testing and certification companies as high-margin compliance annuities, and the core layer re-rates aggressively. |
| Base Case (45%) — A steady grind upward for the core, while grid equipment deflates on schedule | 45% | The number of mandates compounds unevenly. Testing and certification laboratories repair their valuations over three to five years and deliver low-to-mid-teens annualised returns. Rail signalling rises as deadlines approach, while grid equipment valuations compress by 2029 as new global capacity arrives. |
| Bear Case (23%) — Fiscal exhaustion and deregulation cut both ways | 23% | The EU cuts upcoming product-passport and environmental regulations. A new US administration unwinds pharmaceutical tariff pressure, pledged factory construction halves, cheaper foreign certifiers flood the market, and rail signalling deadlines are formally delayed. The portfolio’s limited downside from buying companies that are already cheap becomes the main protection. |
| Anti-Thesis (10%) — The spark fires in the layer we demoted | 10% | Governments solve inspection backlogs by recognising foreign approvals. Duplicated factories are approved on time, and pharmaceutical consumables accelerate in 2027 rather than 2029. Picks-and-shovels stocks rise rapidly while the regulatory layer moves sideways, and grid-equipment firewalls prove harder to breach than modelled. |
The assessment is produced in several steps. Independent model families answer the same question separately and then attack the results. What you read here has survived several rounds.
Any analysis can be wrong. That is why the falsification criteria and the counter-position sit on the same page as the thesis, not in the small print.
The numbers shown against individual companies do not come from this process. The Business-Rating scores business-model quality, the Market-Fit-Rating eighteen fundamental figures against the current market, the Cycle-Rating the valuation against the stock’s own history. They are documented under the Leeway scores.
Leeway rates business quality, fundamental market fit and valuation timing separately. Use the company cards to test the portfolio logic against individual businesses, then read how the ratings are built.
The data is recalculated on a weekly basis and depends on the current market value of the company and the balance sheet figures of the annual financial statements. The market value changes continuously with price changes, the balance sheets are created annually and change the valuation massively. The time of the annual financial statements and the metrics used can be viewed under "Metrics". Further information on how the analyses work can be found as tooltips directly on the analyses as well as in our explanations.
The information is intended to support you in your independent decision-making in implementing investment strategies and serves purely informational purposes. Past performance is not a reliable indication of future performance. No warranty can be given for the completeness, correctness and accuracy of the listed content. The information does not constitute specific investment recommendations. We neither know you nor your financial situation and do not provide investment advice. Only licensed investment advisors with knowledge of your personal circumstances may do this. PWP Leeway UG (limited liability) is not an investment advisor and does not collect any personal data for the purpose of investment optimization. PWP Leeway UG (limited liability) is a provider of investment recommendations and investment strategy recommendations. As such, it is registered with and supervised by the Federal Financial Supervisory Authority (BaFin). The legal notices on the use of the website and the General Terms and Conditions of PWP Leeway UG (limited liability) also apply.
All price data are closing prices of the respective stock exchanges. Price information and master data are provided by an external service provider. Furthermore, public trading data, such as provided by Finra.org, is used to analyze market behavior. No warranty can be given for the completeness, correctness and accuracy of the listed content.
